Does Group Health Cooperative (GHC) Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Get Complicated?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that the body converts to d-amphetamine after absorption. The FDA approved Vyvanse for attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older, and separately for moderate-to-severe binge-eating disorder (BED) in adults. The FDA approval record for lisdexamfetamine is available on the agency's drug database.

Because Vyvanse is a Schedule II controlled substance, every payer, including GHC, applies stricter utilization-management rules than it would to a non-controlled medication. That means prior authorization, step therapy, and quantity limits are standard, not exceptions.

Generic Lisdexamfetamine Changes the Equation

In 2023, the first generic versions of lisdexamfetamine dimesylate entered the U.S. Market following patent expiration. The FDA maintains a list of approved generic equivalents through its Orange Book. Generics are bioequivalent to brand Vyvanse and are subject to FDA's standard requirements for bioequivalence, meaning the same active ingredient at the same dose produces the same pharmacokinetic profile. See the FDA's Orange Book entry for lisdexamfetamine.

On most GHC formularies, generic lisdexamfetamine moves to a preferred generic tier (Tier 1 or Tier 2), carrying a copay of roughly $10, $45 per fill depending on your specific plan. Members who were previously paying $380+ per month for brand Vyvanse often see immediate savings when their prescriber writes the prescription as "lisdexamfetamine dimesylate" or allows generic substitution.

FDA-Approved Indications That Affect Authorization

GHC's prior authorization criteria almost always tie approval to an FDA-labeled indication. The two approved uses are:

• ADHD in patients age 6 and older (adults and pediatric)
• Moderate-to-severe BED in adults

If a prescriber requests Vyvanse for an off-label purpose, GHC will typically deny the request outright under medical necessity criteria. For BED specifically, clinical trial data published in JAMA Internal Medicine (Hudson et al., 2017, N=267) demonstrated that lisdexamfetamine 50 mg and 70 mg significantly reduced binge-eating episodes vs. Placebo (P<0.001). Documenting that trial-level evidence in a prior authorization request strengthens the clinical case considerably.

How GHC Formularies and Tiers Work

Understanding your tier placement determines your out-of-pocket cost before you ever call the pharmacy. GHC, like other insurers operating in Washington State and neighboring markets, publishes a formulary document updated annually. The formulary lists every covered drug with its tier, any utilization-management flags, and quantity limits.

Tier Placement for Vyvanse vs. Generic

Most GHC commercial PPO and HMO plans place drugs as follows:

| Product | Typical Tier | Typical Member Copay | |---|---|---| | Brand Vyvanse 30-day | Tier 3 or Tier 4 (non-preferred brand) | $70, $150+ | | Generic lisdexamfetamine 30-day | Tier 1 or Tier 2 (preferred generic) | $10, $45 | | Mixed amphetamine salts (generic Adderall) | Tier 1 (preferred generic) | $5, $20 | | Methylphenidate ER (generic) | Tier 1 (preferred generic) | $5, $20 |

Exact amounts depend on your specific GHC plan benefit design. Check the Summary of Benefits and Coverage (SBC) document your employer provided at open enrollment, or log into the GHC member portal and search "formulary" for the current year's drug list.

Quantity Limits That Apply

Controlled stimulants face quantity limits on nearly every commercial plan. A common GHC limit for lisdexamfetamine is 30 capsules per 30-day supply, which aligns with DEA regulations prohibiting Schedule II prescriptions from being filled in quantities exceeding a 30-day supply in most states. The DEA's Practitioner's Manual clarifies federal limits on Schedule II prescriptions.

Prior Authorization: Step-by-Step for GHC Members

Prior authorization (PA) for Vyvanse on a GHC plan is a structured process. Missing a single document can delay approval by weeks. Here is the sequence your prescriber's office should follow.

Step 1. Confirm the Formulary Status First

Before starting a PA, have the prescriber's office call GHC pharmacy services (the number appears on your insurance card under "Pharmacy") or use GHC's online provider portal to check whether brand Vyvanse or generic lisdexamfetamine requires a PA on your specific benefit plan. Some employer-sponsored GHC plans have richer formularies that waive the PA for generics.

Step 2. Gather Clinical Documentation

GHC's PA reviewers need, at minimum:

• A confirmed ADHD diagnosis using DSM-5 criteria (or a BED diagnosis meeting DSM-5 severity thresholds)
• Documentation of previous stimulant trials and why they failed (insufficient efficacy, intolerable side effects, or medical contraindication)
• Current symptom severity scores (e.g., ADHD Rating Scale-5 or the Binge Eating Scale)
• Prescriber attestation that the requested dose is medically necessary

The DSM-5 criteria for ADHD require at least 6 of 9 inattentive or hyperactive-impulsive symptoms persisting for 6+ months across two or more settings in children, and at least 5 of 9 symptoms in adults age 17 and older. Insurance reviewers check that documentation against these thresholds.

Step 3. Submit the PA Request

Most GHC PA requests go through the prescriber's office via the online portal or fax. GHC is required under Washington State law to respond to urgent PA requests within 24 hours and non-urgent requests within 3 business days. Keep a confirmation number.

Step 4. If Step Therapy Is Required

GHC plans frequently impose step therapy for Vyvanse, meaning a member must try and fail at least one preferred stimulant before Vyvanse is covered. Typical step-therapy requirements include:

• A trial of generic mixed amphetamine salts (lisdexamfetamine's closest pharmacological relative) for 30 to 90 days, or
• A trial of methylphenidate ER (e.g., generic Concerta) for 30 to 60 days

If those trials produced adverse effects or inadequate ADHD control, that failure documentation becomes your strongest argument for approving Vyvanse.

What to Do If GHC Denies Coverage

A denial is not the end. GHC members have three distinct appeal pathways.

Internal Appeal

Request a formal internal appeal within 60 days of receiving the denial notice. The appeal must include a letter of medical necessity from the prescriber, the clinical documentation described above, and any peer-reviewed literature supporting Vyvanse's specific advantage for your case. A 2016 Cochrane review (Cortese et al.) covering 81 randomized trials and 10,000+ participants ranked lisdexamfetamine among the most effective stimulants for ADHD in adults on standardized mean difference analyses. Citing that review can buttress a medical necessity argument.

External Appeal (Independent Review)

Washington State law grants enrollees the right to an external independent review if the internal appeal is denied. The Washington State Office of the Insurance Commissioner (OIC) administers this process. An independent reviewer, not affiliated with GHC, makes a binding decision. External appeals overturn insurer denials at meaningful rates, particularly for ADHD medications where clinical evidence is substantial.

Exception Request (Step Therapy Exception)

Washington State's step therapy law (SB 5259, effective 2018) allows patients to request a step therapy exception when:

• The required step-therapy drug is contraindicated
• The required drug was previously tried and failed
• The required drug would cause adverse effects based on clinical evidence or the patient's history

Your prescriber files this exception directly with GHC. Approval bypasses the step-therapy requirement without requiring you to complete the full PA track.

Cost-Reduction Strategies While Waiting for Coverage

Even if PA is pending or denied, several options exist to reduce the immediate cash-pay cost of Vyvanse or its generic.

Manufacturer Copay Card (Brand Vyvanse)

Takeda's Vyvanse savings program may reduce the monthly cost of brand Vyvanse to $30 for eligible commercially insured patients. Patients on Medicaid, Medicare, or other government-funded plans are not eligible. Check the manufacturer's current program terms at Takeda's patient support page and note that these programs change annually.

GoodRx and Pharmacy Discount Programs

Generic lisdexamfetamine's retail cash price varies substantially by pharmacy. Discount programs can sometimes reduce the 30-day cash price of generic lisdexamfetamine to $60, $120. These programs cannot be combined with insurance benefits but can be used during PA processing delays.

340B Pharmacies

Patients who qualify for low-income health programs may access brand-name drugs, including Vyvanse, through 340B-participating health centers at significantly reduced prices. The Health Resources and Services Administration (HRSA) maintains the 340B program database.

Dose Optimization

Vyvanse is available in six capsule strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. Some plans apply the same copay regardless of strength. If your prescriber determines a lower dose is clinically adequate, that may reduce your cost-share if the plan calculates copays by days' supply rather than by unit.

ADHD Treatment Guidelines and Where Vyvanse Fits

Knowing what the guidelines say helps you advocate for coverage, because GHC's PA criteria are calibrated against those same guidelines.

American Academy of Pediatrics (AAP) Guidance

The AAP's 2019 clinical practice guideline for ADHD recommends stimulant medications as first-line pharmacotherapy for children age 6 and older. The AAP states: "For elementary school-age children (6-11 years of age), the primary care clinician should prescribe FDA-approved medications for ADHD and may prescribe behavior therapy as treatment." Vyvanse is FDA-approved in this age group.

American Academy of Child and Adolescent Psychiatry (AACAP)

AACAP's practice parameter identifies amphetamine-class stimulants and methylphenidate-class stimulants as equally valid first-line treatments, with selection based on patient-specific factors such as prior response, comorbidities, and duration of effect needed. The AACAP practice parameter is available through PubMed. Lisdexamfetamine's prodrug mechanism produces a smoother onset and offset compared to immediate-release amphetamine, a distinction that can be documented in a PA request when a patient has struggled with the "rebound effect" of shorter-acting agents.

Evidence Base for Lisdexamfetamine in Adults

In a phase 3 key trial (Adler et al., N=420), lisdexamfetamine 30 to 70 mg/day produced statistically significant improvement on the ADHD Rating Scale-IV total score vs. Placebo at week 4 (P<0.0001). That trial is indexed at PubMed. A systematic review in the Journal of the American Academy of Child and Adolescent Psychiatry reported an effect size of 0.89 for lisdexamfetamine on ADHD symptom scales in adults, placing it among the largest effect sizes of any oral ADHD medication studied. See the full review at PubMed.

GHC Medicare and Medicaid Plans: Different Rules

If you are covered through a GHC Medicare Advantage or Medicaid managed-care plan rather than a commercial employer plan, the coverage rules differ materially.

GHC Medicare Advantage

Medicare Part D plans, including those administered through GHC Medicare Advantage, are required to cover Schedule II stimulants for ADHD under the CMS protected class rules, but they may still require PA and step therapy. Manufacturer copay cards cannot be used by Medicare beneficiaries, so out-of-pocket costs for brand Vyvanse on Medicare can exceed $200 per fill until the deductible is met. Generic lisdexamfetamine on Medicare Part D is typically available at the preferred generic tier with a substantially lower copay. CMS publishes Medicare formulary guidelines at cms.gov.

Medicaid (Apple Health in Washington State)

Washington State Medicaid (Apple Health) may cover lisdexamfetamine for ADHD, but brand Vyvanse is unlikely to be covered when a therapeutically equivalent generic is available. The Washington State Medicaid preferred drug list is maintained by the Washington State Health Care Authority. Members should confirm coverage directly with the Health Care Authority or their managed-care plan before dispensing.

Practical Checklist for GHC Members Seeking Vyvanse Coverage

Use this checklist before your next prescriber appointment or pharmacy call.

1. Pull your current GHC formulary PDF (log in to your GHC member portal, search "formulary 2024" or "formulary 2025").
2. Confirm whether your plan covers generic lisdexamfetamine without PA. If yes, ask your prescriber to write "lisdexamfetamine dimesylate" (no brand name) on the prescription.
3. If PA is required, ask your prescriber's office to initiate the PA the same day as your appointment. Delays in PA submission are the most common cause of coverage gaps.
4. Document every previous stimulant trial: drug name, dose, duration, reason for discontinuation. Your prescriber needs this in chart notes.
5. Obtain a DSM-5-based ADHD severity rating at your appointment. Numeric scores (e.g., ADHD-RS-5 total = 32) are more persuasive to PA reviewers than narrative descriptions alone.
6. If denied, request the denial reason code in writing. The specific code tells your prescriber exactly what clinical gap to address in the appeal.
7. Ask your prescriber about Takeda's copay savings program if you are commercially insured and brand Vyvanse is preferred for clinical reasons.
8. If a step-therapy exception applies (contraindication, prior failure, adverse effect risk), file that exception simultaneously with any PA request.

Special Populations: Children, Adolescents, and Pregnant Patients

Pediatric Patients (Age 6 to 17)

GHC PA criteria for pediatric Vyvanse requests typically require documentation from a pediatrician, child psychiatrist, or developmental pediatrician confirming the DSM-5 diagnosis. School-based documentation (teacher rating scales, IEP records) can supplement clinical documentation but does not replace it. Dosing in children starts at 20 to 30 mg/day and can be titrated to a maximum of 70 mg/day. The FDA-approved prescribing information for Vyvanse details pediatric dosing.

Adolescents Transitioning to Adult Care

Adolescents who turn 18 and transition from pediatric to adult insurance coverage through GHC may face a new PA requirement even if they were continuously covered as a dependent. Plan for a gap of up to 2 weeks and initiate the adult PA early.

Pregnancy and Lactation

Vyvanse is classified under the FDA's PLLR (Pregnancy and Lactation Labeling Rule) framework. Amphetamine-class stimulants carry risks during pregnancy, including potential fetal growth restriction. A 2020 population-based cohort study published in JAMA Psychiatry (Bro et al.) found that prenatal amphetamine exposure was associated with increased risk of preterm birth (aOR 1.5, 95% CI 1.3 to 1.8). GHC medical directors may apply heightened scrutiny to Vyvanse PA requests during pregnancy and may recommend non-pharmacologic ADHD management or alternative agents where evidence permits.

When GHC Will Not Cover Vyvanse: Hard Exclusions

Certain situations result in a flat non-coverage determination that cannot typically be overturned on appeal:

• Off-label use without published evidence meeting GHC's medical necessity standards
• Prescriptions written by providers outside GHC's network (for HMO plans that require in-network prescribers)
• Duplicate controlled substance prescriptions from multiple prescribers within the same fill period
• Age <6 years (outside FDA-labeled indication)
• Requests for quantities exceeding 30 capsules per 30-day period (DEA limit)